When was Kimia founded?

Kimia was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is Kimia located?

Kimia is headquartered in Berkeley, United States.

Who is the current CEO of Kimia?

Stig Hansen of Kimia. They have also founded 1 company.

How many employees does Kimia have?

As of Sep 30, 2026, the latest employee count at Kimia is 36.

Is Kimia a funded company?

Kimia is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 20, 2023.

When was the latest funding round of Kimia?

Kimia's latest funding was a $***** Series A round on Dec 20, 2023, with participation from 2 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.88B in funding in 2026 to date.

Where does Kimia rank among its competitors?

Kimia ranks 10th amongst 42 active competitors, of which 15 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Enveda, which secured $311M in Sep, 2026.

Who are the top competitors of Kimia?

Kimia's top competitors include Enveda, Nura Bio and Kvantify. Among them, Enveda secured the most recent funding round in September, 2026.

Kimia - 2026 Company Profile, Team, Funding & Competitors

Kimia is a series A company based in Berkeley (United States), founded in 2023 by Stig Hansen. It operates as a Provider of a next generation drug discovery engine for mall molecule drugs. Kimia has raised $55M in funding from Horizons Ventures. The company has 42 active competitors, including 15 funded and 4 that have exited. Its top competitors include companies like Enveda, Nura Bio and Kvantify.

Company Details

Provider of a next generation drug discovery engine for mall molecule drugs. The company offers a drug discovery engine by combining Chemotype Evolution that enables the rapid synthesis of drugs for novel targets implicated in cancer and immunological disorders.

Website: www.kimiatx.com/
Email ID: *****@kimiatx.com

Key Metrics

Founded Year

2023

Location

Berkeley, United States

Stage

Series A

Total Funding

$55M in 1 round

Latest Funding Round

Series A, Dec 20, 2023, $*****

Investors

Horizons Ventures & 1 more

Ranked

10^th among 42 active competitors

Employee Count

36 as on Sep 30, 2026

Similar Companies

Enveda & 46 more

View Kimia's full profile

Kimia has raised a total funding of $55M over 1 round. Its latest funding round was a Series A round on Dec 20, 2023 for $*****. 2 investors participated in its latest round. Kimia has 2 institutional investors.

Here is the list of recent funding rounds of Kimia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2023	9812968	Series A	2567457	5422576	2514169	1240883

Access funding benchmarks and valuations. Sign up today!

View details of Kimia's funding rounds and investors

The founders of Kimia is Stig Hansen. Stig Hansen is the CEO of Kimia.

Here are the details of Kimia's key team members:

Stig Hansen: Co-Founder & CEO of Kimia and founder of 1 other company.
Contact Info: 1 email address

View details of Kimia's Founder profiles and Board Members

Kimia's employee count trend

Kimia has 36 employees as of Sep 26. Here is Kimia's employee count trend over the years:

Uncover Kimia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kimia include Enveda, Nura Bio and Kvantify. Here is the list of Top 10 competitors of Kimia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enveda 2019, Boulder (United States), Series E	AI-based platform to decipher the chemistry of nature and develop new medicines	$845M	Premji Invest, Kinnevik & 36 others	64/100
2nd	Nura Bio 2018, San Francisco (United States), Series B	Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines	$215M	The Column Group, Sanofi Ventures & 2 others	60/100
3rd	Kvantify 2022, Copenhagen (Denmark), Seed	Provider of quantum computing solutions for businesses in industries such as finance, life sciences, and logistics	$18.9M	Dreamcraft Ventures, Lundbeck Foundation ... & 10 others	57/100
4th	QSimulate 2018, Cambridge (United States), Seed	Laboratory focused on developing of quantitative simulation tools to help in quantum molecular	$11M	2xN, Embark Ventures & 6 others	55/100
5th	Diagonal Therapeutics 2022, Cambridge (United States), Series B	Developer of antibody therapeutics for the treatment of rare diseases	$253M	VF Partners, Atlas Venture & 16 others	55/100
6th	revalia bio 2021, New Haven (United States), Seed	Provider of contract based drugs development services for biopharma sector	$26.8M	Sierra Ventures, AFF & 5 others	54/100
7th	IMIDomics 2015, San Francisco (United States), Series A	Developer of medicines for the treatment of immune-mediated inflammatory diseases	$16.5M	DNS Capital, Evotec & 5 others	51/100
8th	Applied BioMath 2013, Cambridge (United States), Acquired	Systems biology and pharmacology modeling services to aid drug discovery and development	$2.32M	10x Venture Partners, NIH & 1 others	45/100
9th	Cresset 2002, Cambridge (United Kingdom), Seed	Provider of software solutions for computational chemistry	$298K	Scottish Equity Partners, Gov & 8 others	44/100
10th	Kimia 2023, Berkeley (United States), Series A	Provider of a next generation drug discovery engine for mall molecule drugs	$55M	The Column Group, Horizons Ventures	41/100